Paroxetine versus Clomipramine in the Treatment of Obsessive–Compulsive Disorder

  title={Paroxetine versus Clomipramine in the Treatment of Obsessive–Compulsive Disorder},
  author={Joseph Zohar and Rajinder Judge},
  journal={British Journal of Psychiatry},
  pages={468 - 474}
  • J. Zohar, R. Judge
  • Published 1 October 1996
  • Psychology, Medicine
  • British Journal of Psychiatry
Background The aim was to assess the effect of a flexible dose of paroxetine, compared with clomipramine and placebo, in obsessive-compulsive disorder (OCD). Method In a multinational randomised study, 406 subjects with OCD of at least six months duration received double-blind mediation for up to 12 weeks. Doses were adjusted according to therapeutic effect and side-effects. Primary efficacy measures were the Yale–Brown Obsessive–Compulsive Scale and the National Institute of Mental Health… 
A Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder
Results show that venlafaxine was equally effective to paroxetine in treating patients with OCD, and may be a useful therapy for obsessive-compulsive patients, but is not superior to SSRIs.
Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
It is indicated that venlafaxine might be as efficacious as clomipramine in the acute treatment of OCD, with fewer side effects.
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder
Effectiveness of paroxetine in the treatment of obsessive–compulsive disorders
Paroxetine has the broadest treatment spectrum and promises great benefits not only for obsessive–compulsive disorder patients, but also for those with comorbid depression and/or various kinds of anxiety disorders.
Sustained response versus relapse: the pharmacotherapeutic goal for obsessive–compulsive disorder
The results suggest that selective serotonin reuptake inhibitors are effective long-term treatments and relapse prevention represents the treatment target for obsessive–compulsive disorder.
Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder.
During the study's last 28 weeks, sertraline demonstrated greater efficacy than placebo in preventing dropout due to relapse or insufficient clinical response and acute exacerbation of OCD symptoms.
Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond
The pharmacological evidence-base for the treatment of OCD is becoming increasingly robust, and treatment with SSRIs and clomipramine remains uncontroversial and improvements are sustained over time.
Side effects as predictors of drug response in obsessive-compulsive disorder.
Good response, defined as at least a 35% drop in final scores on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), was associated with a later age of OCD onset and certain early side effects that may reflect a sensitivity of responders to CMI's serotonergic actions.
New treatment options for OCD
  • N. Fineberg
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 2007
Escitalopram provides significant symptom relief and prevention of relapse during long-term use and deserves consideration as a first-line agent in the long- term pharmacotherapy of OCD.


Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
Fluoxetine may represent a viable alternative to clomipramine in the treatment of obsessive-compulsive disorder, although further studies with larger sample sizes are needed.
Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Fuvoxamine and clomipramine were equally effective in the treatment of obsessive compulsive disorder; fluvoxamine produced fewer anticholinergic side effects and caused less sexual dysfunction than clomIPramine, but more reports of headache and insomnia.
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.
Fluoxetine was associated with a statistically significant reduction in OCD severity, including time engaged in obsessional and/or compulsive behaviors, and greater efficacy at 60 mg/d was observed.
Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
While the results of this meta-analysis support the superiority of clomipramine, head-to-head, double-blind comparisons of these compounds would be the best test of comparative efficacy and tolerability.
Biological approaches to treatment-resistant obsessive compulsive disorder.
Preliminary evidence suggests that addition of neuroleptic may benefit SRI-refractory obsessive compulsive disorder patients who have a comorbid chronic tic disorder and an algorithm is proposed for those patients with obsessiveCompulsive disorder who fail to respond to an adequate trial with a potent SRI.
An integrated approach to treatment of obsessive compulsive disorder.
  • J. Greist
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1992
Fluvoxamine, fluoxetine, and sertraline, all potent serotonin uptake inhibitors, have also demonstrated efficacy in obsessive compulsive disorder; fluvoxamine is the best studied of these three compounds.
Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.
Results support the safety and efficacy of daily dosages of 50, 100, and 200 mg of sertraline in the short-term treatment of patients with OCD.
Fluoxetine treatment of obsessive-compulsive disorder.
The results suggest that fluoxetine affected depressive symptoms but also had an effect on self-reported measures of obsessions and ritualistic behavior, and patients' ability to tolerate the drug.
A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group.
  • S. Montgomery, A. McIntyre, A. Wood
  • Medicine, Psychology
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
  • 1993
This study supports the growing evidence for the safety and efficacy of fluoxetine in the treatment of OCD.